Submission of Matters to a Vote of Security Holders

Business Context and Reporting Period

This Form 8-K filing by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp) reports on the results of the 2022 Annual Meeting of Stockholders held on June 9, 2022. The company is incorporated in Nevada and trades on the Nasdaq Capital Market under the symbol EKSO.

Key Financial Metrics

This filing is a current report regarding corporate governance and does not contain financial performance data. Revenue, profit, cash flow, margins, debt, and liquidity metrics are not provided in this document.

Material Changes and Voting Results

Of the 12,844,501 shares outstanding, 7,114,626 shares were present, constituting a quorum. Stockholders approved all four proposals:

  • Proposal 1 (Director Election): Six directors were elected. Steven Sherman received the highest number of withheld votes (561,793), while Corinna Lathan received the fewest (235,489). All directors were approved.
  • Proposal 2 (Equity Plan Amendment): Stockholders ratified an increase in the authorized shares for the 2014 Equity Incentive Plan from 1,974,286 to 2,524,286 shares. Votes For: 3,904,027; Votes Against: 621,021.
  • Proposal 3 (Executive Compensation): The advisory vote on named executive officer compensation was approved. Votes For: 4,241,634; Votes Against: 255,063.
  • Proposal 4 (Auditor Ratification): WithumSmith+Brown, PC was ratified as the independent auditor for the year ending December 31, 2022. Votes For: 6,987,669; Votes Against: 55,743.

Guidance, Outlook, and Risks

The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It strictly reports the outcomes of the shareholder vote.

Investor Verification Checklist

  • Verify the company name discrepancy: The input metadata listed "Chronoscale Holdings Corp," but the filing is for "Ekso Bionics Holdings, Inc."
  • Review the Proxy Statement dated April 29, 2022, for detailed executive compensation data referenced in Proposal 3.
  • Monitor the implementation of the increased share authorization for the Equity Incentive Plan approved in Proposal 2.
  • Check subsequent filings (10-K or 10-Q) for the financial metrics absent in this 8-K.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.